<DOC>
	<DOCNO>NCT01348412</DOCNO>
	<brief_summary>Standard treatment metastatic colorectal cancer relies fluoropyrimidines , irinotecan alone association fluoropyrimidines , oxaliplatin association fluoropyrimidines , bevacizumab anti EGFR antibody . After failure classical regimen national reference frame basis phase II study propose association fluoropyrimidine mitomycin . These treatment give response rate 10-20 % progression free survival 2 3 month . Hepatic intra-arterial chemotherapy logical case isolate hepatic metastasis nonaccessible curative resection : 1 ) hepatic metastasis vascularize hepatic arterial system contrast nontumoral hepatic parenchyma ; 2 ) arterial perfusion oxaliplatin lead strong extraction liver first passage , high intra-tumoral concentration low systemic concentration . So oxaliplatin drug choice arterial treatment combination fluoropyrimidines impossible need prolong perfusion . Floxuridin available France . Raltitrexed , definitive inhibitor thymidylate synthase , require prolonged perfusion could good substitute.In previous pilot study demonstrate feasibility , safety efficacy combination raltitrexed oxaliplatin arterial perfusion . Now propose phase II randomize clinical trial evaluate efficacy hepatic arterial infusion raltitrexed oxaliplatin association versus standard chemotherapy patient metastases colorectal origin restrict liver failure conventional chemotherapy .</brief_summary>
	<brief_title>Hepatic Arterial Chemotherapy With Raltitrexed Oxaliplatin Versus Standard Chemotherapy Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>Informed consent signature patient Cover health insurance Age 18 75 year Age 76 et 80 year patient WHO Status 0 WHO status 0 1 Estimated Life expectancy &gt; 3 month Hepatic metastasis colorectal cancer confirm CT Scan without extrahepatic metastasis ( presence asymptomatic primary tumor tolerate ) TEPScan without fixation outside liver primary tumor Histological proven colorectal cancer obtain primary tumor hepatic metastasis Metastases accessible curative hepatectomy ( impossible R0 surgery leave less 30 % residual liver ) , require complex , wide hepatectomy ( 5 segment ) and\or risky procedure ( RPC Class II ) Presence hepatic lesion &gt; 10 mm CTScan hepatic MRI Failure arrest previous chemotherapy intolerance oxaliplatin , irinotecan , fluoropyrimidine and/or target therapy ( bevacizumab , cetuximab panitumumab give tumor express wild type KiRas ) Bilirubinemia &lt; 1,5 time superior limit normal ( N ) , ASAT ALAT &lt; 5 N , Creatinemia &lt; 1.5 N creatinine clearance &gt; 65ml/mn , Neutrophils &gt; 1,5 x 109/L , platelet 100 x 109/L , hemoglobin &gt; 9 g/dL ( patient includables even red blood cell transfusion ) Reference CTScan +/MRI perform 21 day precede first cycle treatment extrahepatic metastasis ( presence 1 3 pulmonary nodule , maximal diameter 5 mm non specific aspect CTScan fixation TEP Scan constitute criterion exclusion ) Symptomatic primary colorectal tumor place Contraindication allergy rank 34 one compound chemotherapy Peripheral neuropathy &gt; 2 ( Levy Scale ) Current participation 30 day precede inclusion study another therapeutic trial experimental molecule Concomitant systemic treatment immunotherapy , chemotherapy hormonotherapy Unbalanced serious illness , unchecked active infection underlie serious disorder susceptible prevent patient receive treatment Pregnancy ( pregnancy test compulsory inclusion ) , breastfeed Intestinal occlusion subocclusion history inflammatory intestinal disease Other cancer 5 year precede entry trial concomitant ( except situ cancer cervix skin basal cell carcinoma ) Patient custody guardianship , Impossibility adhere medical followup geographical , social psychiatric reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>non resectable metastasis</keyword>
	<keyword>liver colic rectal origin</keyword>
	<keyword>failure conventional treatment</keyword>
</DOC>